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Abstract
Strychnine acts as an inhibitor of post-synaptic neuronal inhibition 
and intoxication leads to distinct clinical manifestations which may 
culminate in death. Since its commercialization is prohibited in 
most countries, cases of strychnine intoxication are now rare. We 
present a case of an elderly patient who voluntarily ingested a white 
powder thought to be strychnine. He developed myoclonus, startle 
response, and episodes of generalized muscle contractions accom-
panied by respiratory arrest in one occasion. Diazepam, valproic 
acid and supportive treatments were able to control manifestations, 
however the patient died after 2 days. Our aim is to alert clinicians 
that, despite its rarity, strychnine intoxication may still be seen in 
emergency departments, and clinical outcome can be influenced by 
rapid recognition and timely institution of adequate treatment.
Keywords: Strychnine; Intoxication; Glycine antagonist; General-
ized muscle contractions; Startle.
Introduction
Strychnine, a white powder alkaloid derived from the seeds 
of the tree Strychnos nux-vomica, has had its use, through-
out history, as an antiseptic, stomach tonic, circulatory and 
central nervous system stimulant and, more recently, as a 
poison for animal control [1]. In the European Union, where 
it had its use as a rodenticide, authorities have prohibited 
its sale in 2003 and recalled all supplies in 2006. Neverthe-
less, rare intoxication (accidental or deliberated) reports due 
to strychnine continue to be published in medical literature, 
some with the patient being discharged alive [2, 3]. Pharma-
cologically it is a competitive antagonist of glycine, an im-
portant inhibitory neurotransmitter in the ventral horns of the 
spinal cord, brainstem, and higher centers [4]. It undergoes 
extensive metabolism by hepatic cytochrome P-450 2B, has 
a biological half-life of 10 - 12 hours, and up to 20% is ex-
creted unchanged in the urine within 24 hours [5]. Despite its 
rarity, strychnine intoxication distinct manifestations should 
not be forgotten. This is especially true for clinicians work-
ing in the emergency department, since rapid identification 




We present the case of an 87-year-old white male, brought 
to the emergency department by his family after a suspect-
ed ingestion of strychnine. The patient was a retired forest 
ranger and had no previous history of mental illness. His past 
medical history was significant for chronic kidney disease, 
hyperuricemia, diabetes mellitus, and osteoarthritis. His 
medications included gliclazide, allopurinol, alprazolam, 
cobamamide and glucosamine. At admission, he had no 
complaints, denied any type of poison ingestion and asked to 
be discharged. When questioned, the patient admitted pos-
sessing a bottle of strychnine powder for about twenty years. 
His daughter insisted that she had seen him ingesting a small 
amount of a white powder after a familial dispute. Presenting 
vital signs and physical examination were significant only 
for anxiety and paroxysmal jerky movements of the extremi-
ties. Admission blood tests results are shown in Table 1.
The patient was kept under observation and 12 hours 
after white powder ingestion, while being repositioned in 
bed, he developed a series of powerful repetitive generalized 
tonic muscle contractions with preserved consciousness, cul-
minating in respiratory arrest. Contractions resolved after IV 
administration of 10 mg of diazepam and bag-valve-mask 
ventilation. Progressive recovery of consciousness was ob-
served. He was transferred to an intermediate care unit. By 
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then the patient was fully awake and orientated, restless, with 
adequate speech and generalized hyperreflexia. An exuber-
ant generalized startle response could be elicited by minimal 
tactile and auditory stimuli. Each startle response elicited a 
series of repetitive generalized extension tonic muscle con-
tractions, prominent trismus and facial muscles contraction, 
with apparent preserved consciousness, accompanied by 
transient desaturation and difficult spontaneous ventilation, 
without the need of ventilation support. These episodes were 
self-limited, resolved more quickly and were less frequent if 
the patient was maintained in a low light, sound and move-
ment ambiance. Analytical study showed lactic acidosis, 
slightly elevated myoglobin and white cell count - see Table 
1 (Day 1) for more detail. Brain CT scan was unremark-
able. Symptomatic treatment with sodium valproate, initial 
dose of 750 mg, followed by a 1,600 mg (1 mg/kg/h) 24 
h perfusion, led to termination of the muscle contractions. 
Elevated myoglobin and lactic acidosis were managed with 
fluid therapy. Reduction of frequency and intensity of the 
startle response occurred progressively. Albeit resolution of 
symptoms, the patient died 2 days after emergency depart-
ment initial admission, following a cardiogenic pulmonary 
edema that did not respond to standard of care attitudes.
Discussion
  
It is well known that symptoms begin 5 to 30 minutes after 
strychnine intake, as it is readily absorbed by all routes. Clin-
ical effects of ingestion have been seen at doses as small as 2 
mg in a child and 20 mg in an adult [1]. The dose-dependent 
effects remain controverse. It is difficult to define a lethal 
dose as the published data are variable from one study to an-
other, but it is possible to admit that it is situated between 30 
- 100 mg [3]. By competing with glycine for glycinergic re-
ceptors (prevents the entrance of chloride, in the cell, that is 
responsible for a hyperpolarization and therefore stabilizing 
the membrane potential, diminishing the neuron excitabil-
ity), strychnine inhibits post-synaptic inhibition, leading to 
increased motor neuron activity [3]. Classical manifestations 
may include a swift prodromal stage with anxiety, increased 
sense of awareness and hyperreflexia followed by a well 
documented clinical stage with nystagmus, risus sardoni-
cus, trismus, intense generalized muscle contractions with 
preserved consciousness, tactile, auditory and visual stimuli 
hypersensitivity which may culminate in respiratory arrest 
and death within hours after ingestion due to contraction of 
the diaphragm, thoracic and abdominal muscles [5]. Sus-
tained muscle contractions can lead to rhabdomyolysis, renal 
failure, hyperthermia and lactic acidosis. Vomiting, cardiac 
rhythm alterations, arterial hypertension and other analyti-
cal alterations like leukocytosis have also been described 
as symptoms of strychnine intoxication (Fig. 1). Other con-
ditions such as tetanus, epileptic seizures, CNS infections, 
drug withdrawal syndromes, and amphetamine intoxication, 
may have similar manifestations. Nevertheless time course, 
clinical history and neurological examination are helpful for 
differentiating these conditions. Despite the delayed onset of 
overt clinical symptoms with generalized muscle contrac-
tions and startle response, an anxious patient with occasional 
myoclonus of the extremities was initially described, con-
stituting a prolonged, not yet reported in literature, prodro-
mal stage of strychnine intoxication. Confirmation can be 
attained by qualitative or quantitative strychnine analysis in 
body fluids or tissues, not available at our institution or in a 
timely fashion in other nearby facilities. Since the clinical 
index of suspicion was very elevated regarding the possibil-
ity of strychnine intoxication, further attempts in confirming 
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Figure 1. Clinical manifestations and complications of strychnine intoxication adapted from S Arzalier-Daret and D. 
du Cheyron [3].
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its presence were not pursued. Treatment is supportive and 
includes benzodiazepines like diazepam (reports of use of 1 
mg/kg [1]), lorazepam and clonazepam, GABA receptor-act-
ing anticonvulsants (it may counteract the strychnine effect 
at the postsynaptic membrane by its inhibitory effect in the 
motor neuron [3]), mostly phenobarbital and sodium valpro-
ate (no specific dosages are described in literature), neuro-
muscular blocking agents, like atracurium or vecuronium, if 
previous muscle contractions controlling attempts were not 
successful, oxygen and airway support, as well as prevention 
of hemodynamic and metabolic complications (see above) 
[2, 3]. Gastric lavage and induced emesis must be carefully 
considered, given the risk of precipitating motor manifesta-
tions that can culminate in death it may be attempted after 
the control of muscle contractions. Despite successful treat-
ment of involuntary movements with diazepam and sodium 
Variable Reference Range Admission Day 1 Day 2
Hematocrit (%) 40 - 49.5 35.2 29.4 29.9
Hemoglobin (g/dL) 13.5 - 17 11.9 9.7 9.9
White cell count (103/μL) 4 - 10.5 8.6 12.7 14.6
Platelet count (103/μL) 166 - 308 236 202 184
Creatinine (mg/dL) 0.6 - 1.3 1.6 1.5 1.8
Urea (mg/dL) 15 - 39 35 37 52
Sodium (mmol/L) 136 - 145 138 149 149
Potassium (mmol/L) 3.5 - 5.1 4.2 5 3.5
Chloride (mmol/L) 98 - 107 102 114 114
Bilirrubin total (mg/dL) 0.2 - 1.0 0.63 1.3 0.8
Lactate dehydrogenase (U/L) 87 - 241 101 101 115
Calcium ionized (mmol/L) 1.15 - 1.35 1.21 1.21 1.12
Magnesium (mg/L) 18 - 24 20 16
Phosphorus (mg/dL) 2.5 - 4.9 3.2 3
Creatine Kinase (U/L) 39 - 308 18 117 116
Myoglobin (ng/mL) 16 - 116 66 390 186
Troponin I (ng/mL) < 0.1 < 0.02
Alanine Aminotransferase (U/L) 12 - 78 14 19 9
Aspartate Aminotransferase (U/L) 15 - 37 13 20 19
NT-Pro B-Type Natriuretic Peptide (pg/mL) < 450 1,976 4,584
Arterial Blood Gas
pO2 (mmHg) 70 - 100 86 136 82
pCO2 (mmHg) 35 - 46 38.9 38.5 36
pH 7.37 - 7.45 7.44 7.31 7.33
HCO3- (mmol/L) 21 - 26 26 19 19
Lactate (mmol/L) 0.5 - 2 0.82 6.66 1.34
Table 1. Blood Tests Results
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valproate, and adequate supportive treatment, the patient 
died after a cardiogenic pulmonary edema, probably due to 
excessive IV fluids administration allied with presumed, and 
previously not known, heart failure (elevated NT-Pro B-type 
Natriuretic Peptide) (Table 1) in a diabetic elderly. Confir-
mation of the cause of death was only possible if an autopsy 
had been performed, which was not requested by the family.
Definite confirmation of strychnine intoxication requires 
its identification in blood, gastric fluid or urine samples, 
nowadays unavailable at the majority of institutions. The 
clinical picture described, even though with a delayed onset 
never reported to this date, strongly suggests this diagnosis. 
Since it is a substance no longer commercialized and thus 
not present in our every day routine, it calls for an extremely 
suspicious mind to timely rise this clinical hypothesis. When 
typical clinical manifestations are recognized early, appro-
priate treatment can result in a good outcome [2, 3].
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